
ROCHE HOLDING AG-BR signed a drug-discovery partnership with Atavistik Bio worth up to $2B on Thursday afternoon. The deal focuses on developing oral treatments for cardiovascular, kidney, and metabolic diseases. The agreement spans multiple targets and includes $70M upfront alongside $1.9B in milestone payments.










